ImmunoCellular Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of ImmunoCellular Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 30th, investors have sold 100 shares of IMUCD short.

ImmunoCellular Therapeutics saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 100 shares, a decline of 91.7% from the previous total of 1,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of ImmunoCellular Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ImmunoCellular Therapeutics: ULURU Inc. (0.00%), Acura Pharmaceuticals, Inc. (0.00%), BetterLife Pharma Inc. (0.00%), Parnell Pharmaceuticals Holdings Ltd (0.00%), GlobeImmune, Inc. (0.00%), Kaya Holdings, Inc. (0.00%), Immune Therapeutics, Inc. (0.00%), Cotinga Pharmaceuticals Inc. (0.00%), BriaCell Therapeutics Corp. (0.00%), and Intellipharmaceutics International Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.91 billion), Aon plc ($3.68 billion), ViacomCBS Inc. ($2.95 billion), The Clorox Company ($2.92 billion), Analog Devices, Inc. ($2.35 billion), Uber Technologies, Inc. ($2.27 billion), Moderna, Inc. ($2.14 billion), The Kroger Co. ($2.14 billion), Datadog, Inc. ($2.00 billion), and Simon Property Group, Inc. ($1.85 billion). View all of the most shorted stocks.

Short selling IMUCD is an investing strategy that aims to generate trading profit from ImmunoCellular Therapeutics as its price is falling. ImmunoCellular Therapeutics' stock is trading up $0.03 today. To short ImmunoCellular Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that ImmunoCellular Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ImmunoCellular Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMUCD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMUCD, twice per month. The most recent reporting period available is September, 30 2020.